Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of JNJ-54861911 in Healthy Older Males
NCT02260700Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2013
- Primary completion
- Nov 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atabecestat in Alzheimer's disease (AD) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 96 hours, Time to Reach Maximum Plasma Concentration at 96 hours and 5 more. Started Sep 2013; status: completed.
02
Drugs
atabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02260700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02260700.